CHDI’s goal is to increase the understanding of Huntington’s disease (HD) and to hasten the development of therapies.We collaborate with academic and industrial scientists throughout the world.
This website highlights activities that may be of particular interest to people engaged in or contemplating HD research and provides information on targets, compounds, and research materials that HD researchers may find useful.
Please join our mailing list
News Headlines
-
09/06/2011
CHDI Foundation appoints new Chief Clinical Officer
CHDI Foundation, Inc. has appointed Cristina Sampaio, MD, PhD to the newly-created position of Chief Clinical Officer.
-
09/06/2011
Galenea and CHDI Foundation announce collaboration
Galenea Corp. and CHDI Foundation, Inc. have announced a collaboration to identify synaptic dysfunction linked to Huntington’s disease (HD) utilizing Galenea’s proprietary synaptic transmission drug discovery platform. Galenea’s innovative platform will provide new insights into the disease mechanism.
Upcoming Scientific Events
-
February 27- March 1, 2012
7th Annual HD Therapeutics Conference
The Parker Hotel, Palm Springs, CA
Creative Commons Attribution 3.0 United States License.
